阿巴西普（CTLA4-Ig）不断演变的临床概况：一种用于治疗类风湿关节炎的新型共刺激调节剂
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
作者信息
Ruderman Eric M, Pope Richard M
机构信息
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
出版信息
Arthritis Res Ther. 2005;7 Suppl 2(Suppl 2):S21-5. doi: 10.1186/ar1688. Epub 2005 Mar 16.
Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate the T cell co-stimulatory signal mediated through the CD28-CD80/86 pathway. Clinical trials have provided preliminary evidence of the efficacy of this compound in the treatment of rheumatoid arthritis. This review describes the molecular and biologic bases for the use of abatacept in rheumatoid arthritis and summarizes the current clinical data on its safety and effectiveness in this disease.
阿巴西普（CTLA4-Ig）是一种新型融合蛋白，旨在调节通过CD28-CD80/86途径介导的T细胞共刺激信号。临床试验已提供了该化合物治疗类风湿关节炎有效性的初步证据。本综述描述了阿巴西普用于类风湿关节炎治疗的分子和生物学基础，并总结了目前关于其在该疾病中安全性和有效性的临床数据。
Zotero 插件